Rapport Therapeutics, Inc. Common Stock (RAPP) support and resistance · rev $20.0M
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
This page maps Rapport Therapeutics, Inc. Common Stock (RAPP) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
RAPP currently screens at market cap $532.9M. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new RAPP 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the RAPP quote page for the session range and the stock page for the full model.
Not investment advice.